Episode Details

This episode delves into the critical definition of a "significant change" for legacy medical devices and IVDs under the EU MDR and IVDR. We explore the official MDCG guidance, outlining what types of modifications can end a device's transitional grace period, forcing an early and costly move to full certification. Learn about the high-stakes impact on market access and the importance of a robust change control process. - What is a "legacy device" and what are the new transition timelines? - How can a minor change to a device jeopardize its EU market access? - What is the difference between a significant and non-significant change? - Which MDCG guidance documents are essential for your change control process? - Why is changing a supplier a regulatory grey area? - What are the immediate consequences if a change is deemed significant? - How should you document and justify changes to your Notified Body? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We specialize in navigating complex transitions like the EU MDR and IVDR, offering services in Regulatory Strategy, Technical Dossier preparation, and Continuous Regulatory Monitoring to ensure your products remain compliant. Our unique combination of local expertise in over 30 markets and advanced AI tools streamlines global market access. Let us help you manage change control and maintain your market presence without disruption. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.